




REFERENCES

REFERENCES

Alien, J.B., Manthe, C.L. and Hand A.R. (1990):

Rapid onset synovial inflammation and hyperplasia induced by TGF- β 1
Exp .Med., 117:231-247

Altman, R., Asch, E., Bloch, D. and Bole, G. (1986):

Development of criteria for classification and reporting of OA of the knee.
Arthri. Rheum. Vol. 29, No. 8: 1039-1050

Altman, R.D. (1995):

Classification of OA.
J. Rheumatol., 22 (Suppl: 43): 42-43.

Amento, E.P. and Beck, L.S. (1991):

TGF- β 1 and wound healing.
Ciba Found Symp., 157:115-123.

Apley, A.G., Soloman, L. and Mankin, H.J. (1993):

OA and related disorders. In:Apley's system of orthopedics and fractures, 7th
edition. Ed by Apley AG, Soloman L and Mankin HJ., Butterworth
Heinmann., Pp: 80-92.

Arend, W.P. and Dayer, J.M. (1995):

Inhibition of the production and effects of IL-1 and TNF- α in rheumatoid
arthritis.
Arthritis Rheum., 38: 151-160.

Arend, W.P., Dayer, J.M. (1995):

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor in Rheumatoid arthritis.

Arthritis Rheum., 38: 15

Bendtze, K., Severson, M., Jenssen, V. and Hippe, J. (1990):

Auto-antibodies to cytokines-friends or foes?

Immunol. Today, 11: 167.

Beooks, Pand Day, R. (1991):

NSAIDs: Differences and similarities.

N. Eng. J. Med., 324: 1716-25.

Bettens, F., Walkers, C., Gauchet, J.F., Gaucher, D., Wyss, T. and Pinchler, W.J. (1989):

Lymphokines gene expression related to CD4 T cell subset phenotype conversion.

Eur. Immunol., 19: 1569.

Betz, M. and Fox, B.S. (1991):

Prostaglandin E2 inhibits production of TH1 lymphokines but not TH2 lymphocytes.

J. Immunol., 146: 18

Blobe, O., Lodish, M. and Schimann, T. (2000):

Role of TGF- β in human diseases.

New England Journal of Medicine 4: 1350-1358.

Border, W.A. and Ruoslahti, E. (1991):

TGF in diseases :the dark side of tissue repair.

J. Clin. Invest., 90:1-7.

Brandes, A.B., Kuruvilla, A.B., Shah, R., Hochwald, G.M. and Liggitt, H.D.(1991):

Protective effect of TGF- β 1 on experimental diseases in mice

Proc. Natl. Acad. Sci. USA, 88:2918-2921.

Brandes, M.E., Allen, J.B., Ogawa, Y. and Wahi, S.M. (1991):

TGF- β 1 suppresses acute and chronic arthritis in experimental animals.

J. Clin. Invest., 87:1108-1113.

Brandley, J.D., Brandt, K.D.,Katz, B.P. and Ryan, S.L.(1991):

Comparison of an analgesic dose of ibuprofen and acetaminophen in the treatment of OA of the knee.

N. Eng. J. Med., 325: 87-91

Brandt, K.D. and Fife, R.S. (1986):

Aging in relation to the pathogenesis of OA..

Clin. Rheum. Dis., 12:17

Brandt, K.D. and Flusser, D.(1991):

OA prognosis in rheumatic disease. Ed. by Bellamy N, Klumer Academic Publisher, Lan Caster, pb: 11-35

Brandt, K.D. and Mankin, H.J. (1993):

Pathogenesis of OA : etiological factors. In: textbook of Rheumatology, 4th edition. Ed. by Kelly WN, Harris ED, Ruddy S and Sledge CB, WB. Saunders Inc., Philadelphia; vol. 3: 1365-73. .

Brandt,K.D.(1994):

OA. in Textbook of harrison's principles of internal medicine,13th edition. Ed. by Isselbacher, K.J., Martinn,J.B., Brounwalt,E., Fauci, A.S.,Willson,J.D. and Casper,D.L., Vol. 4, No.5:1689-92

Brandt, K.D. (1995):

Toward pharmacologic modification of joint damage in OA..
ANN. Intern. Med., 122: 874-75

Brewer, I.J., Kathy, M.D. and Cochras, M.C. (1998):

The arthritis source book.
NTC contemporary publishing group.

Buckwalter, J.A. and Lohmander, S. (1994):

Operative treatment of osteoarthritis: current practice and future development.
J. Bone joint Surg., 76 A: 1405-18.

**Bulter, M., Calomba, C., HickmanL, O., Byrne, E., Stecte, R., Steintz, B.,
Quintvalla, J. and Yokoyama, N. (1983):**

A new model of OA. In rabbits II, evaluation of anti- arthritic effects of
selected drugs administered intra-articular.
Arthritis Rheum., 26: 1132-39.

Burrows, F.J. (1995):

Up-regulation of vascular epithelium in human solid tumor.
Clin. Cancer Res. 1: 1632-84.

Cromack, D.T., Porras, R.B., and Mustoe, T.A. (1990):

Current concepts in wound healing: growth factor and macrophage interaction.
J. Traumatol., 30:129-133.

Davis, L.S., Geppert, T.D., Meek, K., Oppenheimer-Marks, N. and Lipky, R.B. (1997):

T cells and B cells. In Text book of Rheumatology, fifth edition, edited by: Kelly WN, Herris ED, Ruddy S and Sledge C., WB Saunders Company, Philadelphia, London, Toronto, Tokyo, p. 95.

Davis, M.A., Ettinger, W.H. and Neuhaus, J.M. (1990):

Obesity and osteoarthritis of the knee: Evidence from the National Health and Nutrition Examination survey (NHANESI).
Semin Arthritis Rheum., 20(suppl.1): 34-41.

Davis, M.A., Ettinger, W.T., Neuhaus, J.M. and Hauck, W.W. (1988):

Sex differences in OA of the knee: the role of obesity.
Am. J. Epidemiol., 127: 1019-30.

Dayer, J.M. and Arend, W.P. (1997):

Cytokine and growth factors.

In Textbook of Rheumatology, fifth edition, edited by: Kelly WN, Herris ED, Ruddy S and Sledge C., WB Saunders Company, Philadelphia, London, Toronto, Tokyo, p. 76.

Dean, D.D. (1991):

Protease mediated cartilage degradation in OA.
Semin Arthritis Rheum., 20(suppl 1): 2.

Dinarello, C.A. (1993):

Modalities for reducing IL-1 activity in disease.
Immunol. Today, 142: 813.

Edelson, R., Burks, R.T. and Bloebaum, R.D.(1995):

Short term effects of knee wash-out for OA. .
Ann. J. Sports Med., 23 (3): 345-49.

Eyre, D.R., Weis, M.A. and Moskowitz, R.W. (1999):

Cartilage expression of a type II collagen mutation in an inherited form of OA associated with mild chondrodysplasia.
J. Clin. Invest., 87: 357-61.

Felson, D.T., Naimark, A., Anderson, J.J. and Kazis, L. (1987):

The prevalence of knee OA in the elderly. The Framingham OA study.
Arth. Rheum., 30: 914

Fife, R.S. (1994):

Osteoarthritis. IN: principles of geiatric Medicine and Gerontology, 3rd edition , ed. by Hazzard WR, Bierman EL, Blass JP, Ettinger WH and Halt JB.
Mc Graw-Hill; New York; Pp: 981-86.

Fife, R.S., Brandt, K.D., Braunstein, E.M., Katz, B.P., Shelbourne, K.D., Kalosinski, L.A. and Ryan, S. (1991):

Relationship between arthroscopic evidence of joint space narrowing and chronic knee pain in early OA of the knee.

Arthritis Rheum., 34: 377-82.

Frenkel, S.R., Saadeh, P.B., Mehrara, B.J., Chin, Gs., Steinbrech, D.S., Brent, B., Gittes, G.K. and Longaker, M.T. (2000):

TGF- β superfamily members: role in cartilage remodeling.

Plast Reconstr. Surg. Mar; 105(3): 980- 90

Furst, D.E. (1994):

Are there differences among NSAIDs? Comparing acetylated NSAIDs. Arthr. Rheum.,37: 1-9.

Goei, T.H., Lund, B., Distel, M. and Bluhmki, E. (1997):

A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of OA of the knee.

Osteoarthritis Cartilag., 5: 283-88.

Grawford, A., Awad, B. and Goto, S. (1998):

TGF- β 1 in autoimmune hepatitis.

Development 124: 2659-2668.

Gray, R.G. and Gottlin, N.L. (1983):

Intra-articular corticosteroids.

Orthop., 177: 235.

Griffin, M.R. (1989):

Practical management of OA: Integration of pharmacologic and non-pharmacologic measures.

Arch. Famil. Med., 4: 1049-55.

Griffin, M.R., Pifer, J.N., Snowden, M. and Ray, W.A. (1991):

Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons.

Ann. Intern. Med., 114:257.

Griffin, M.R. (1994):

published trials of non medical and non invasive therapies for hip and knee osteoarthritis.

Ann. Intern Med., 121: 133-40.

Grove, R.J. (1993):

Oncostatin M is a mitogen for rabbit vascular smooth muscle cells Proc. Natl. Acad. Sci, USA., 90: 90- 99.

Harvey Siman, M.D., Masha, J., Elkin, M.D., John, E., Godline, M.D., Daniel, M.D. and Theodore, M.D.(1998):

OA: Nidus information services, INC.

Hoch berg, M.C. (1991):

Epidemulogy of OA: current concepts and new in rights.

J. Rheumatol., 18(27): 1-6.

Hunziker, M.R. (2001):

growth factors induced healing of partial-thickness defects in adult articular cartilage.

Osteoarthritis Cartilage, 9 (1): 22-32

Hutton, C. and Dieppe, P.(1988):

Genetics of OA..

Clinical Rheumatology; vol. 2, No. 3: 703-10.

Idem,H.j. (1990):

The TGF- β 1. In Hand book of experimental pharmacology ed. by Sporn MB and Roberts AB (eds). Peptide growth factors and their receptors.New York, Springer-Verlage, 95:pp 419.

Jahag, J.S., Lee, J.W., Han C.D., and Yoo N.C.(1997):

Transforming growth factor- beta 1 responsiveness of human articular chondrocytes in vitro :normal versus osteoarthritis.

Yonsei Med. J., 38 (1) : 40 – 51

Jain, J., MC-Caffrey,P.G., Valge, A.V. and Rao, A.(1992):

Nuclear factor of activated T cells.

Nature, 356:801

Johnson Ferry, R.D. and Marietta, G.A. (1999):

What is OA of the knee.

The center for orthopedics and sports medicine.

Kellgren, J.H. (1963):

Atlas of standard radiographs. the epidemiology of chronic rheumatism.
Oxford : Black-Well.

Kellgren, J.H. and Lawrence, J.S. (1957):

Radiological assessment of OA.
Ann. Rheum. Dis., 16: 494-502

Kemp, P. R., Grainger, D.J. and Metcalfe, J.C. (1995):

The serum concentration of active TGF-B is severely decreased in advanced atherosclerosis.
Nature Med. 1: 74-79.

Kishimoto, T. (1987):

B cell stimulatory factors (BSFs) molecular structure biological function and regulation of expression.
J.Clin. Immunol , 7: 343.

Kitamura, M. and Suto, T.S. (1997):

TGF-B anti-inflammatory action.
Nephrol. Dial. Transplant, 17: 669-679.

Kraus, V.B. (1997):

Pathogenesis and treatment of osteoarthritis.
Adv. Rheumatol., 81 : 85 - 112

Lafeber, F.P., Vankoy, H.L. and Vander kraan, P.M.(1997):

TGF-beta predominantly stimulates phynotypically changed chondrocytes in osteoarthritic human cartilage.

J. Rheumatol., 24 (3): 536-42

Letterio, J.J. and Roberts, A.B. (1998):

Regulation of immune response by TGF-B.

Annu. Rev. Immunol., 16: 137-61.

Li, B., Khanna, H. and August,J. (1999):

TGF-B polymorphism, protein level and blood pressure.

Hypertension; 33: 271-75.

Linden, B., Distel, M. and BLuhmki, E. (1996):

A double- binds study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with OA of the hip.

BR. J. Rheumatol., 35 (suppl. 1): 35-8.

Lipsk, P.E., Davis, L.S., Cush, J.J. and Oppenhimer-marks, N. (19989):

The role of cytokines in pathogenesis of rheumatoid arthritis

Immunopathol., 11: 123.

Liu, J. (1993):

F K 506 and cyclosporine, molecular probs for studying intracellular signal transduction.

Immunol. Today, 14: 290.

Mac Neil, I.A., Suda, T., Moore, K.W., Mosmann, T.R. and Zlotnik, A.(1990):

IL-10 a novel growth cofactor for mature and immature T cell.
J. Immunol., 145: 4167.

Maehara, E., Panthel, N. and Marcen, C. (1999):

Cutaneous wound healing.
Proc. Nalt. Aci. Sci. USA 97: 2626-2631

Mankin, H.J. (1989):

Clinical features of OA. In: Textbook of Rheumatology, 3rd edition. Ed. by
Kelly, W.N., Harris,E.D., Ruddy S and Sledge C., WB.
Saunders Inc., Philadelphia; Pp: 1480-98.

Mankin, H.J. (1993):

Clinical features of OA. In:Textbook of Rheumatology, 4th edition. Ed by
Kelly WN, Harris, EDJr, Ruddy S and Sledge C., WB.
Saunders Inc., Philadilphia Pp: 1374-84.

Mansell, J.P., and Bailey, A.J. (1998):

Abnormal cancellous bone collagen metabolism in osteoarthritis.
J. Clin. Invest., 101(8): 1596-1603

Marc, J.P., Roy, D. and Altman,J.(1995):

Guidelines for the medical management of OA..
American Collage of Rheum. Vol. 38, No. 11, November Pp 1541-1546

Massague, J. (1990):

TGF-B family.

Annu. Rev. Cell Biol., 6: 597-641.

Massague, J. (1996):

TGF- β 1 signaling :receptors, transducers and Mad proteins.

Cell, 85:947-950.

Massague, J. (1998):

TGF- β 1 signal transduction.

Annu. Rev. Biochem., 67: 753-91.

Masuda, E.S., Naito, Y., Arai, K.I. and Arai, N. (1993):

Expression of lymphokine genes in T cells.

The Immunologist, 1: 198.

Mazieres, B., Loyau, G., and Menkes, C.J.(1992):

Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis: 5 – month results of amulticenter double-blind controlled prospective study using placebo.

Revue Rheum. Mal. Osteoartic ; 59(7-8): 466-72(fre).

Mc-Alindon, T.E., Cooper,C. Lirwan, T.R. and Dieppe,P.A.(1992)

knee pain and disability in the community.

Br. J. Rheumatol., 31:189-92.

Mc-caffery, T.A., Consilling, J. and Forrest, N.(1999):

Cardiac remodeling in female taking tamoxifen for breast cancer.

BMJ., 311: 977-988.

Mercola, J. (1998):

Treatment of OA..

J. Clin. Invest., 35: 101.

Moskowitz, R.W. (1976):

Clinical and laboratory findings in OA IN: Arthritis and Allied Conditions, 1st edition. Ed. by Hollander JL and McCarty DJ, Saunders Inc., Philadelphia, Pp: 1932-39.

Moskowitz, R.W. (1999):

Bone remodeling in osteoarthritis.

Osteoarthritis cartilage, 7(3): 323-24

Mosley, B., Beckmann, M.B., March, C.J. and Idzerda, R.L (1989):

The murine IL-4 receptor: Molecular cloning and characterization of secreted membrane bound form.

Cell; 54: 335.

Moss, V., Fickert, S., Muller, B., Weber, V. and Sieper, J. (1999):

Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage .

J. Rheumatol., 26 : 70.

Muller- Fabender, H., Bach, G.L. and Haase, W. (1994):

Glucosamine sulfate compared to ibuprofen in OA of the knee. Osteoarthritis cartilage; 2(3): 61-9.

Nancy, E. and Lane, M.D.(1999):

Management approaches of OA.

Division of Rheumatology, University of California, Sanfrancisco, School of Medicine.

Neustadt, D.H. (1992):

Intra-articular steroid therapy. In: OA: diagnosis and management, 2nd edition.

Ed. by Moskowitz RW, Howell DS, Goldberg VM and Mankin HJ., WB.

Saunders Inc., Philadelphia, Pp: 493-510.

Nisha, M.D. and Manek, M.R. (2000):

OA: current concepts in dignosis and mamagement.

Stanford Univerisity Medical Center,Palo Alto, California.

Nisha, M.D., Manek, M.R. and Nancy, M.D. (2001):

OA current concept in diagnosis and management.

The American Academey of family physicians.

Nogaard, P. (1995):

TGF-B and cancer.

Cancer. Treat. Rev. 21: 367-403.

Norton, S.D., Havinen, D.E. and Jenkins, M.K. (1991):

IL-2 secretion and T cell clonal anergy and induced by distinct biochemical pathway.

J. Immunol.,146: 1125.

Okuda,M.D. (2000):

Age-dependant expression of TGF-beta 1 and it's receptors and age related stimulatory effects of TGF-beta 1 on proteoglycan synthesis in rat intervertebral discs.

Journal of Musculoskeletal Research, Vol. 4, No. 3; 101-109

Oppenheim, J.J. And Ruscetti, F.W. (1997):

Cytokines in rheumatoid arthritis.

Ann.Med. 23: 219-223

Oshima, M., Oshima, H. and Taketo, H.J. (1996):

TGF- β type II receptors defect .

Dev. Biol., 179: 297-302.

Paulus, H.E. and Bulfitt, K.J. (1993):

Nonsteroidal anti-inflammatory agents and corticosteroids. IN: primer of the rheumatic diseases, 10th edition. ED. by Schumacher HR, Kilppel JH and Koopman WJ . Arthritis Foundation, Atlanta, Georgia, Pp202-303.

Pelletier, J.P. and Martel-Pelletier, J. (1989):

Protective effect of corticosteroids on cartilage lesions and osteophytes formation in the Paul-Nukidog Model of osteoarthritis and Rheum.,3:1815-20

Pepper, M.S. (1997):

Angiogenesis and vessel wall integrity.

Cytokine growth factor Rev. 8: 21-48.

Perrella, M.A., Hsieh, C. and Leew, Y. (1996):

Arrest of endotoxin-induced hypotention by TGF- β Proc. Nalt. Acad.Sci. USA
93: 2045-2059.

Pick, E., Stefes, A. and Geotz, R.P. (1999):

The link between hyperglycemia and diabetic nephropathy.

Diabetes, 44:80-92.

Pujol, P. (1999):

TGF-beta and osteoarthritis.

Osteoarthritis Cartilage, 7 (5): 39-40

Quill, H., Gaur, A. and Philpps, R.P. (1989):

Prostaglandin E2 dependant induction of granulocyte-macrophage colony
stimulating factor secretion by cloned murine helper T cells.

J. Immunol., 142:813.

Quin, L., Kuncio, M.D. and Jin, Y. (1994):

Biochemical events and cytokines interaction linking glucose metabolism and
diabetic complication.

Science; 272: 699-700.

Rasmussen, R., Takatsu, K., Harada, N., Takahashi, T. and Bottomly, K. (1988):

T cell dependent hapten specific and polyclonal B cell responses require release of IL-5.

J. Immunol., 140: 705.

Rehman, M.D. and Nancy, E. (1999):

Control of OA pain.

Post graduate Medicine, vol. 106/No 4: 1027-37

Robb, R.J. (1984):

Interleukin-2. The molecule and its function.

Immunol. Today 5:203

Robert, A.B. and Sporn, M.B. (1989):

Peptide growth factors and their receptors in the Hand book of Experimental Pharmacology, Ed. by Sporn MB and Roberts AB (eds).

New York, Springer-Verlage, 4: pp 419.

Roitt, I.M., Brostoff, J. and Mala. D. (1998):

Cell mediated immune reaction: in Immunology, fifth edition, edited by: Roitt IM, Brostoff J, Mala D, Mosby ST, Louis, London, Philadelphia, Sydney and Tokyo, p. 121.

Romagnani, S. (1994):

Lymphokine production by human T cell in disease states.

Annu. Rev. Immunol., 12: p. 227

Rosen, F., McCabe, G., Quach, J., Solan, J. and Lotz, M. (1997):

Differential effects of aging on human chondrocyte responses to TGF- β 1: Increased pyrophosphate production and decreased cell proliferation. *Arthritis Rheum.*, Jul. 40(7): 1275-81

Rovati, L.C. (1992):

Clinical research in OA: design and results of short term and long term trials with disease-modifying drugs.

Int. J. Tissue React., 14(5): 243-51.

Ruoslahti, E. and Yamaguchi, Y. (1991):

Proteoglycans as modulators of growth factor activities.

Cell 64:867-9.

Ruoslahti, E. (1991):

Integrins.

J. Clin. Invest., 87:1-5.

Sarafino, E.P.(1990):

Health psychology: Biopsychosocial interaction, 1st edition. Ed. by sarafino EP, Wiley Publishers, New York, Pp: 62-9.

Schiott, A., Widegren, B., and Lindvall, M. (1999):

Transforming growth factor – β 1, a strong costimulator of rat T-cell activation promoting a shift towards a Th2-like cytokine profile.

Immunol. Lett., 67(2): 131-9

Schultz, G., Chegini, N. and Grant, M. (1992):

Effects of growth factors on corneal wound healing.

Acta. Ophthalmol., 202:60-66.

Schumacher, H.R. (1993):

Secondary OA. In OA: Diagnosis and Management, 1st edition. Ed. by Moskowitz RW, Howell DS, Goldberg VM and Mankin HJ., WB. Saunders Inc., Philadelphia; Pp 667-98.

Shah, S.V., Foreman, D.M. and Ferguson, M.D.

(1995):

Neutralization of TGF- β 1 and β 2 or exogenous addition of TGF- β 3 to cutaneous wound reduce scarring.

T Cell Sci., 108: 983-1002.

Shari, M., Ling, D.M., Joan, M. and Bathon, M.D.(2001):

What factors are responsible for inducing metalloprotease synthesis ?

The Johns Hopkins Arthritis center.

Shaw, J.P., Meervovitch, J.K., Cleackley, R.C. and Peatkau, V. (1988):

Mechanisms regulating the level of IL-2 mRNA in lymphocytes.

J. Immunol; 140:2243.

Shlopov, B.V., Guman, O.V., Skaya, M.L. and ^H~~L~~asty, K.A. (2000):

Autocrine regulation of collagenase 3(matrix metalloproteinase 13) during osteoarthritis.

Arthritis Rheum. Jan; 43(1): 195-205

Siedman D.S., Evet, H. and Gale, R. (1989):

The effect of maternal weight gain in pregnancy on birth weight.

Obest. Gynecol., 74 (2): 240-6

Smith, J.E., Giri, J.G. and Dower, S.K. (1980):

The two IL-1 receptors play different roles in IL-1 actions.

Clin. Immunol. Immunopathol., 372: 9

Spector, D.D., Hart, D.T., and Huskinson, E.C. (1991):

The use of radiography in assessing the severity of OA .

J. Rheum., 18: 38.

Sporn, M.B. and Roberts, A.B. (1993):

A major advance in the use of growth factors to enhance wound healing.

J. Clin. Invest., 92: 2841-49.

Street, N.E. and Mosmann, T.R. (1991):

Functional diversity of T Lymphocytes due to secretion of different cytokine patterns.

FASEB J. 5:171.

Taibale, J., Sahrinen, J. and Keski-O.J. (1998):

Extracellular matrix assoiated factor-B.

Adu. Cancer Res. 75: 87-93.

Thomas, R.H., Resnick, D., Alasraki, N.P. and Daniel, D.(1975):

Compartmental evaluation of OA of the knee.

J. Diagnostic Radiol. 116: 585-594.

Trinchieri, G. (1993):

IL-12 and its role in the generation of TH1 cells.

Immunol. Today, 14 : 335.

Trinchieri, G. and Scott, P. (1994):

The role of IL-12 in The immune response, disease and therapy.

Immunol. Today, 15: 460.

Uchino, M., Izumi, T., Tominaga, T., Wakita, R., Minchara, H., Sekiguchi, M. and Itoman, M.(2000):

Growth factor expression in the osteophytes of the human femoral head in osteoarthritis.

Clin. Orthop., 377: 119-25

Vander Den Kraan, P.M. and Vanden Berg, W.B. (2000):

Anabolic and destructive mediators in osteoarthritis. .

Clin. Nutrition Metabolic care. Vol.7, No.3:214-219

Vansuuse, J.L., Van Romand, L.K.J., Cats, A., Vanden, T.P. and Valken, H.A.(1989):

Epidemiology of OA. Zittermeas survey. Comparison of radiological OA in Dutch population, compared with that in 10 other population.

Ann. Rheum. Dis., 48: 721-80.

Vassalli, P. (1992):

The pathophysiology of tumour necrosis factor.

Ann. Rev. Immunol., 10: 411-522.

Villanneva, A., Garica and Paules, A.B. (1998):

Disruption of the antiproliferative TGF-B signaling pathways in human pancreatic cancer cells.

Oncogene 17: 1969-78.

Vogel, G. (1999):

A new blocker for the TGF-B pathway.

Science, 268: 665.

Wakefield, L.M., Smith, D.M. and Sporn, M.B. (1998):

Latent TGF-B from human platelets.

J. Biochem., 263: 7646-7656.

Waldmann, T.A. (1991):

IL-2 receptors.

J. Biol. Chem., 266: p.2681.

Wang, J. (1995):

Inactivation of type II TGF-B receptor in colon cancer cells with microsatellite instability.

Science, 268: 1336-1338.

Waren, D.J. and Moore, M.A.(1988):

Synergism among IL-1 and IL-3 and IL-5 in the production of eosinophils from primitive hematopoietic stem cell.

J. Immunol., 145: 4167

Williams, H.G., Ward, J.R. and Egger, M.J. (1993):

Comparison of naproxen and acetaminophen in a two year study of treatment of OA of the knee.

Arthritis Rheum., 36: 1196-1206.

Woolf, Y., Kwan, M.K. and Cutts, R.D. (1992):

Biochemical consideration. IN Moskowitz RW, Howell DS, Goldberg VM, Mankin HJ(eds): Osteoarthritis: Diagnosis and medical/surgical management 2nd edition. Philadelphia, WB Saunders, Pp 191-211.

Yang, X., Leliterio, J.J. and Kier, A.B. (1999):

Impaired mucosal immunity and diminished T cell responsiveness to TGF- β .

EMBO J. 18: 1280-90.